Curis Raises $8.5M PIPE at $0.51 and Reprices 4.86M Existing Warrants to $0.60
CRIS sits 17% above its 52-week low of $0.325.
Summary
Curis priced an $8.5 million private placement at a combined $0.51 per share and simultaneously slashed the strike on roughly 4.86 million existing warrants to $0.60, buying runway only through December 2026 CLL data.
Key Events · Financing and Capital Events · CRIS
-
PIPE Priced at $0.51 Combined
16,666,680 shares (or pre-funded warrants at $0.50) sold at a combined $0.51 with an accompanying common warrant struck at $0.60, for gross proceeds of about $8.5 million.
-
Existing Warrants Repriced to $0.60
January 2026 warrants (1,126,676 shares, was $15.00) and August 2026 warrants (3,733,334 shares, was $1.50) were amended down to $0.60; a separate August 14, 2026 warrant was cut from $1.75 to $0.60 by holder consent.
-
Runway Only Through December 2026
Proceeds are expected to fund operations only through initial CLL data in 5-10 patients in December 2026, following the Q2 10-Q's substantial doubt about going concern and runway into Q4 2026.
-
Agent Fees and Registration Penalties
A.G.P. and Laidlaw receive a 6.5% cash fee plus up to $85,000 legal reimbursement and $10,000 non-accountable expenses; the resale registration carries 1.0% per 30-day liquidated damages capped at 6.0% of invested amounts.
Analysis · CRIS · Life Sciences
Curis is raising $8.5 million through a private placement of 16.67 million shares (or pre-funded warrants) at a combined $0.51, each paired with a common warrant struck at $0.60. The cash is modest, and the company says it funds operations only through initial CLL data in 5-10 patients in December 2026 — against a backdrop where the Q2 10-Q already flagged substantial doubt about going concern and runway into Q4 2026. The bigger structural change is the warrant repricing: 1.13 million January warrants cut from $15.00 and 3.73 million August warrants cut from $1.50, plus a separate August 14 warrant cut from $1.75, all down to $0.60. That pulls roughly 4.86 million potential shares much closer to the money, so future exercises are far more likely to become real share issuance. Placement agents take a 6.5% cash fee plus up to $95,000 in expenses, and the registration rights carry 1% per 30-day liquidated damages if the resale filing slips.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $797.6K. The 52-week trading range was $0.33 to $33.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.